PhaseBio Pharmaceuticals, Inc. (PHASQ)

PhaseBio Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2021	2020	2019	2018	2017
Revenue	0.01	0.32	2.36	0.67	0
Revenue Growth (YoY)	-96.62%	-86.45%	253.44%	-	-
Cost of Revenue	0	0.32	0	0	0
Gross Profit	0.01	0	2.36	0.67	0
Selling, General & Admin	0.02	13.09	11.19	4.86	2.33
Research & Development	0.1	72.09	30.91	15.46	6.21
Operating Expenses	0.12	85.18	42.1	20.31	8.54
Operating Income	-0.13	-84.86	-39.74	-19.64	-8.54
Interest Income	0	0.24	1.58	0.39	0.05
Interest Expense	-0	1.45	1.08	3.92	2.72
Other Expense / Income	0	24.77	-1.55	0.94	-1.98
Pretax Income	-0.13	-98.57	-39.25	-23.85	-10.25
Income Tax	0	-12.26	1.57	-0.28	1.01
Net Income	-0.13	-98.57	-39.25	-23.85	-10.25
Shares Outstanding (Basic)	29	29	27	5	11
Shares Outstanding (Diluted)	29	29	27	5	11
Shares Change	1.18%	5.68%	418.25%	-52.85%	-9.21%
EPS (Basic)	-0.00	-3.39	-1.43	-4.49	-0.91
EPS (Diluted)	-0.00	-3.39	-1.43	-4.49	-0.91
Free Cash Flow	-50.1	-61.37	-40.55	-17.17	-8.48
Free Cash Flow Per Share	-1.70	-2.11	-1.48	-3.24	-0.75
Gross Margin	100.00%	0.10%	100.00%	100.00%	-
Operating Margin	-1204.12%	-26517.50%	-1683.02%	-2940.72%	-
Profit Margin	-1210.15%	-30801.56%	-1662.30%	-3569.76%	-
Free Cash Flow Margin	-462515.00%	-19177.81%	-1717.66%	-2570.66%	-
EBITDA	1.66	-96.61	-38	-19.82	-7.43
EBITDA Margin	15350.22%	-30191.25%	-1609.36%	-2966.62%	-
Depreciation & Amortization	1.79	0.51	0.17	0.11	0.1
EBIT	-0.13	-97.12	-38.17	-19.92	-7.52
EBIT Margin	-1204.12%	-30350.00%	-1616.73%	-2982.34%	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.